Guggenheim analyst Jason Cassorla raised the firm’s price target on Universal Health (UHS) to $253 from $227 and keeps a Buy rating on the shares after the company reported Q3 results that largely were inline to better than buyside expectations across both Acute and Behavioral. UHS reorienting focus toward Behavioral outpatient, which over time should allow a more fulsome capture of Behavioral share, supports a higher value for shares, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Universal Health Services Reports Strong Q3 2025 Results
- UHS Earnings Call: Mixed Outlook with Strong EPS Growth
- Universal Health Services: Strong Growth and Strategic Expansion Drive Buy Rating with $251 Price Target
- Universal Health price target raised to $190 from $165 at BofA
- Universal Health’s Mixed Q3 Performance and Stable Outlook Justify Hold Rating